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Abstract
Background: Diabetes is a risk factor for developing Alzheimer’s disease (AD); however, the mechanism by which
diabetes can promote AD pathology remains unknown. Diabetes results in diverse molecular changes in the brain,
including dysregulation of glucose metabolism and loss of cerebrovascular homeostasis. Although these changes
have been associated with increased Aβ pathology and increased expression of glial activation markers in APPswe/
PS1dE9 (APP/PS1) mice, there has been limited characterization, to date, of the neuroinflammatory changes
associated with diabetic conditions.
Methods: To more fully elucidate neuroinflammatory changes associated with diabetes that may drive AD
pathology, we combined the APP/PS1 mouse model with either high-fat diet (HFD, a model of pre-diabetes), the
genetic db/db model of type 2 diabetes, or the streptozotocin (STZ) model of type 1 diabetes. We then used a
multiplexed immunoassay to quantify cortical changes in cytokine proteins.
Results: Our analysis revealed that pathology associated with either db/db, HFD, or STZ models yielded
upregulation of a broad profile of cytokines, including chemokines (e.g., MIP-1α, MIP-1β, and MCP-1) and pro-
inflammatory cytokines, including IL-1α, IFN-γ, and IL-3. Moreover, multivariate partial least squares regression
analysis showed that combined diabetic-APP/PS1 models yielded cooperatively enhanced expression of the
cytokine profile associated with each diabetic model alone. Finally, in APP/PS1xdb/db mice, we found that
circulating levels of Aβ1-40, Aβ1-42, glucose, and insulin all correlated with cytokine expression in the brain,
suggesting a strong relationship between peripheral changes and brain pathology.
Conclusions: Altogether, our multiplexed analysis of cytokines shows that Alzheimer’s and diabetic pathologies
cooperate to enhance profiles of cytokines reported to be involved in both diseases. Moreover, since many of the
identified cytokines promote neuronal injury, Aβ and tau pathology, and breakdown of the blood-brain barrier, our
data suggest that neuroinflammation may mediate the effects of diabetes on AD pathogenesis. Therefore, strategies
targeting neuroinflammatory signaling, as well as metabolic control, may provide a promising strategy for
intervening in the development of diabetes-associated AD.
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Introduction
Alzheimer’s disease (AD) is the most common cause of
dementia [1]. It is characterized neuropathologically by
the progressive appearance of senile plaques composed
of aggregated amyloid beta (Aβ), followed by microglial
and astrocytic immune responses, formation of neurofib-
rillary tangles, neuronal dystrophy, and neuronal death
[2, 3]. While aging remains the main risk factor for AD,
the association between type 2 diabetes (T2D) and AD is
particularly robust, as evidenced by epidemiological
studies and supported by molecular, functional, and clin-
ical data [4–7]. Also, prediabetes, as an initial step to
later develop T2D, has been associated with AD [8, 9],
and previous studies have suggested a role for type 1
diabetes (T1D) in AD [10, 11]. At the molecular level,
some relevant links between diabetes and AD have been
found. Among others, (i) insulin receptors are highly
expressed in CNS regions relevant for cognition and
memory, such as the cortex and hippocampus, and insu-
lin has been shown to influence memory [12, 13]; (ii) Aβ
oligomers induce insulin resistance in hippocampal neu-
rons, suggesting a type of brain diabetes that may link
Aβ to memory deficits [14]; and (iii) neurovascular dam-
age impairs Aβ clearance along interstitial-fluid drainage
pathways [15, 16], and both high Aβ and high glucose
can compromise vascular health. In fact, the coexistence
of metabolic diseases in mouse models of AD exacer-
bates AD hallmarks and memory deficits in these mice,
as well as the inflammatory process associated with AD,
prediabetes, and diabetes [11, 17]. Further, anti-diabetic
drugs protect cognitive functions in AD mouse models
and AD patients [18, 19].
Although the relationship between diabetes and AD
might be attributed to some or all of the aforementioned
factors [20], the ultimate cause of AD remains elusive.
Individuals with unusually high levels of Aβ and/or
neurofibrillary tangles do not necessarily suffer from
cognitive decline or neuronal loss, and these resilient
cases differ from AD patients in that they exhibit a re-
duced level of glial activation markers GFAP and Iba-1
[21], thus suggesting a role for the brain’s immune sys-
tem in AD. The inflammatory response to AD is initi-
ated by microglia, which migrate towards Aβ plaques
and surround them. Microglial cells then secrete pro-
inflammatory cytokines, including IL-1, IL-6, and TNF-
α, as well as chemokines, such as MIP-1α and MCP-1,
that attract astrocytes to envelop the plaques [22, 23].
Whether these glial responses are protective or deleteri-
ous is a matter of debate. One line of thought is that
microglial and astrocytic responses reflect a protective
immune function aimed at sequestering and degrading
plaques. However, there is mounting evidence that glial
responses to secreted cytokines and Aβ contribute to
AD pathogenesis by producing factors that can be
neurotoxic, like nitric oxide. Moreover, certain cyto-
kines, such as TNF-α, IFN-γ, IL-6, and VEGF in
combination with Aβ also contribute to neuronal death
[24, 25], and IL-6 can upregulate amyloid precursor pro-
tein synthesis and processing, thereby accelerating
plaque formation and disease progression [26]. However,
due to the multiple functions and cross-talk of different
cytokines, univariate analyses of cytokines do not pro-
vide a holistic picture of the neuroinflammatory micro-
environment in pathological or control conditions. In
light of these challenges, we have previously used multi-
variate analysis to correlate brain cytokine profiles with
AD severity and to identify previously unnoticed cyto-
kines that may play specific roles in disease progression
[25]. We also used this type of analysis to identify dis-
tinct profiles of cytokines that may distinguish patients
resilient to AD pathology from both controls or patients
with AD [27].
In the present study, we used multivariate analysis
tools to profile brain cytokine protein expression in the
APPswe/PS1dE9 (APP/PS1) mouse model of AD amyl-
oid pathology. We studied the APP/PS1 model alone or
in combination with either a prediabetic state induced
by a high-fat diet (APP/PS1-HFD), a well-established
T1D induced by streptozotocin (APP/PS1-STZ), or a
well-established T2D induced by crossing APP/PS1 mice
with the classic T2D mouse model db/db (APP/PS1xdb/
db). We describe correlations found between cytokine
expression and pathological hallmarks and identify cyto-
kines that may dissect specific aspects of these disease
combinations, opening the door to establish different
cytokine profile signatures associated with AD, prediabe-
tes, T2D, or the combination of these commonly associ-
ated diseases.
Material and methods
Animals and treatments
APP/PS1 mice were obtained from the Jackson Labora-
tory (Bar Harbor, ME, USA) [28, 29]. Prediabetes was in-
duced by HFD (60% Kcal from fat, OpenSource, New
Brunswick, NJ, USA) ad libitum administration to APP/
PS1 mice from 4 to 26 weeks of age, as previously de-
scribed [30]. All other groups were fed with regular diet
(SAFE A04. Augy, France). T1D diabetes was induced in
wildtype and APP/PS1 mice at 18 weeks of age by intra-
peritoneal (i.p.) injection of streptozotocin (STZ, 40 mg/
kg) for five consecutive days. STZ-treated mice were
aged to 26 weeks. db/db mice were used as a model of
T2D, and mixed AD-T2D mice were obtained by cross-
ing db/db with APP/PS1 mice as previously described
[11] and were also aged to 26 weeks of age. Both males
and females were included in the study, as noted in the
figure legends [11, 17, 30, 31]. Animals were sacrificed
by intraperitoneal pentobarbital overdose (120 mg/kg).
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Left hemispheres were dissected and flash frozen and
stored at − 80 °C until used. Right hemispheres were
fixed in PFA 4%, and 30 μm coronal sections were ob-
tained on a cryostat (Microm HM525, Thermo Scien-
tific, Spain).
All experimental procedures were approved by the
Animal Care and Use Committee of the University of
Cadiz and Junta de Andalucía (09-07-15-282) in accord-
ance with the Guidelines for Care and Use of experi-
mental animals (European Commission Directive 2010/
63/UE and Spanish Royal Decree 53/2013).
Metabolic assessment
Body weight and postprandial glucose levels and insulin
levels were determined in all mice under study at 26
weeks of age as previously described [17, 18]. Metabolic
assessment was performed in the morning (8:00–11:00
a.m), immediately before sacrifice. Blood was collected
at sacrifice. Glucose levels were measured with a gluc-
ometer Optium Xceed (Abbott, USA). Plasma was sepa-
rated by centrifugation (7 min at 6500 rpm), and insulin
levels were measured by ultrasensitive insulin ELISA ac-
cording to the manufacturer’s indications (Mercodia
Inc., Winston Salem NC) [17, 18].
Aβ levels
Soluble and insoluble Aβ40 and Aβ42 levels were quan-
tified by colorimetric ELISA kits (Wako, Japan) as previ-
ously described with minor modifications [17].
Somatosensory cortex (5–10mg) was homogenized in
50 μl of lysis buffer (Pierce™ IP Lysis Buffer, cod. Cat
87787 Thermo Scientific, Spain) with Halt protease in-
hibitor cocktail 100x (cod. cat1862209 Thermo Scien-
tific, Spain) and centrifuged at 14,500 rpm and 4 °C for
12 min. For soluble Aβ40 and 42 levels, supernatants
were diluted 1:300 in H2Odd prior to running the
ELISA. For insoluble Aβ levels, pellets were extracted
with 65 μl of 70% formic acid and centrifuged at 14,500
rpm and 4 °C for 10 min. After neutralizing with 1M
Tris (pH 11), samples were diluted (1:10) in standard di-
luent from the ELISA kit. Blood samples were extracted
immediately before sacrifice and centrifuged at 6500
RPM for 7 min. Plasma was collected and diluted 1:2 in
ddH2O for quantification of Aβ40 and 42 via ELISA
(Wako) according to the manufacturer’s protocols.
Absorbance was measured spectrophotometrically at
450 nm (MQX200R2, Biotek instruments, Burlington
VT, USA), and data were expressed as pmol/g tissue or
pmol/L of plasma.
Aβ and microglia immunostaining
Right hemisphere sections were selected at 1.5, 0.5, − 0.5,
− 1.5, − 2.5, and − 3.5mm from Bregma [32]. Sections
were pretreated with formic acid (70%) and incubated
with anti-Iba1 (Wako, Osaka, Japan) (1:1000) and anti-Aβ
(4G8, Covance, Greenfield, IN, USA) (1:2000) antibodies
at 4 °C in 0.5% BSA overnight. Alexa Fluor 594 and Alexa
Fluor 488 (Molecular Probes, OR, USA) (1:1000) were
used as secondary antibodies. A Laser Olympus U-RFL-T
fluorescent microscope (Olympus, Japan) and MMIcell-
Tools v.4.3 (Molecular Machines and Industries, Eching,
Germany) software was used was used to for image acqui-
sition. Senile plaque (SP) burden and microglia burden in
proximity of (within 50 μm) and far from (> 50 μm) SP
were measured using Image J software as previously de-
scribed [17].
Statistical analysis
One-way ANOVA followed by Tukey b test, Tamhane
test, or Dunnett’s test as required were used. SPSS v.24
and GraphPad Prism 7 (GraphPad Prism, San Diego,
CA) software was used for all statistical analysis. Outliers
were removed using GraphPad Prism’s robust regression
and outlier removal (ROUT) method.
Luminex analysis of cytokines
Brain cortices were homogenized and lysed using a Bio-
Plex cell lysis kit (BioRad, 171-304011), with the addition
of protease inhibitor cocktail (Thermo Scientific Pierce,
Spain) following the manufacturer’s directions. Lysates
were centrifuged at 14,500 rpm and 4 °C for 12 min. Su-
pernatants were stored at − 80 °C until used. Protein
content was determined by Bradford assay [33]. Samples
were normalized to 7.5 μg/μl in 0.5% bovine serum
solution, and 50 μL of each sample was added to the
Bio-Plex kit. Cytokine protein was quantified using the
Bio-Plex Pro™ Luminex Cytokine panel (BioRad 10,014,
905) and read out using a Bio-Plex Manager Software v
6.0 and Bio-Plex 200 system (Bio-Rad, Spain). Data were
expressed in pg/mg total protein, by Bradford analysis
[33]. G-CSF was excluded from analysis because it was
not detectable above background.
Partial least squares modeling
Partial least squares regression (PLSR) and PLS discrim-
inant analysis (PLSDA) were conducted in MATLAB
using the partial least squares algorithm by Cleiton
Nunes (Mathworks File Exchange). All data were z-
scored, and then directly inputted to the algorithm. For
each PLSDA and PLSR analysis, an orthogonal rotation
in the LV1-LV2 plane was used to choose a new LV1
that better separated groups or phenotype/Y-variable, re-
spectively. A Monte Carlo subsampling of 80% of the
samples with 1000 iterations without replacement was
used to compute SDs for LV signals. To correct for sign
reversals, each subsampled LV1 and LV2 was multiplied
by the sign of the scalar product of the new LV and the
corresponding LV from the total model. When ANOVA
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was used to analyze scores on both LV1 and LV2,
orthogonality was checked for and the scalar pro-
duct between the two components was ensured to
be < 1 × 10−15.
Results
Metabolic alterations
Body weight, glucose, and insulin levels were used to
quantify metabolism of each animal model at 26 weeks
of age. Weight and metabolic measurements (insulin
and glucose) were not significantly affected in APP/PS1
animals compared to wild-type mice (Additional file 1:
Figure S1A). However, there is the possibility that more
subtle alterations may be present [34], and we did not
detect significant differences due to limited statistical
power. In prediabetic mice (HFD and APP/PS1-HFD),
body weight and insulin levels were increased, consistent
with a prediabetic phenotype (Additional file 1: Figure
S1A). T1D was induced by STZ treatment for five con-
secutive days starting at 18 weeks of age–8 weeks prior
to assessment of metabolism and pathology. STZ and
APP/PS1-STZ mice presented a modest reduction in
body weight. Insulin levels were reduced in STZ-treated
mice, and hyperglycemia was detected (Additional file 1:
Figure S1A). T2D mice (db/db and APP/PS1xdb/db)
were overweight and both plasma insulin and glucose
levels were significantly increased (Additional file 1:
Figure S1A).
Amyloid pathology was altered in diabetic models
As previously observed, metabolic disease affected the
kinetics of amyloid deposition in APP/PS1 mice. In par-
ticular, we observed that senile plaque (SP) burden was
significantly reduced in STZ-treated APP/PS1 (T1D-AD)
and in APP/PS1xdb/db (T2D-AD) mice compared to
APP/PS1 mice [F(3,21) = 11.81, **p < 0.01 vs. APP/PS1-
STZ and APP/PS1xdb/db] (Additional file 1: Figure
S1B). Similar changes were observed when we measured
insoluble Aβ levels (Aβ40 [F(3,18) = 5.66, **p < 0.01 vs.
rest of the groups]; Aβ42 [F(3,18) = 6.43,
††p < 0.01 vs.
APP/PS1-HFD) (Additional file 1: Figure S1B). However,
soluble Aβ levels were increased in APP/PS1xdb/db
mice (Aβ40 [F(3,18) = 16.12, **p < 0.01 vs. rest of the
groups]; Aβ42 [F(4,18) = 16.96, **p < 0.01 vs. rest of the
groups]) (Additional file 1: Figure S1B).
Microglial burden
Microglia burden was measured in close proximity to SP
(< 50 μm) or far from SP (> 50 μm). An overall increase
in microglia burden was observed in SP-free areas within
T2D mice [F(7,42)=4.68, **p = 0.001 vs. control and APP/
PS1] (Additional file 1: Figure S1C and D) whereas no
differences were detected in proximity to SP [F(7,21) =
1.98, p = 0.147] (Additional file 1: Figure S1C and D).
Our observations are in line with previous studies from
our lab analyzing microglia burden in these animal
models [11, 17, 30, 31], and microglia appear to be more
amoeboidal in the vicinity of senile plaques (Additional
file 1: Figure S1D).
STZ type 1 diabetic model stimulates cytokine production
in APP/PS1 mice
Since STZ-induced T1D pathology reduced SP burden
in APP/PS1 mice (Additional file 1: Figure S1B), we hy-
pothesized that this alteration in pathology would be ac-
companied by an enhanced neuroinflammatory response
in APP/PS1-STZ mice compared to APP/PS1 mice at
the 26-week time point. To test this, we used Luminex
analysis (Bio-Rad) to quantify protein expression of 22
cytokines/chemokines in mouse cortical tissues. G-CSF
levels were under detection limits for the majority of the
animals under study and G-CSF was thus excluded. Our
analysis showed that STZ treatment induced robust
cytokine expression in APP/PS1 mice compared to un-
treated controls (Additional file 1: Figure S2). Since we
were primarily interested in the differences in cytokine
expression of APP/PS1-STZ combined pathology com-
pared to either APP/PS1 or STZ pathology alone, we
represented the panel of cytokines in terms of their z-
scores (mean subtracted and normalized to standard de-
viation) with respect to these three groups (Fig. 1a). To
account for the multi-dimensional nature of our data,
we used a partial least squares discriminant analysis
(PLSDA) to identify composite profiles of cytokines,
called latent variables (LV1 and LV2), that distinguished
between groups, as we have done previously [25, 27, 35]
(Fig. 1b). LV1 consisted of a weighted profile of cyto-
kines that together distinguished APP/PS1-STZ com-
bined pathology mice from either pathology alone
(Fig. 1c, d), while LV2 distinguished STZ from APP/PS1
pathology (Fig. 1e, f). While scoring the individual sam-
ples on LV2 revealed that STZ-induced T1D pathology
significantly upregulated that cytokine profile compared
to APP/PS1 pathology, more interestingly, scoring sam-
ples on LV1 revealed that APP/PS1 with STZ-induced
T1D pathology robustly increased scores on the LV1
cytokine profile compared to either pathology alone
(Fig. 1d). A similar trend was observed when analyzing
each cytokine on an individual basis (Additional file 1:
Figure S3). Importantly, the cytokine weights in LV1
identify those cytokines that most strongly discriminate
between combined APP/PS1-STZ pathology and the
other groups. The top cytokines on LV1, MCP-1, IL-1α,
IL-3, and IL-17 all have strongly pro-inflammatory and
chemotactic properties [36–41]. Therefore, these data
indicate that the STZ-induced T1D condition contri-
butes to an elevated pro-inflammatory environment in
the context of amyloid pathology.
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Db/db T2 diabetic model cooperatively stimulates
cytokine production in APP/PS1 mice
Since microglial burden and amyloid levels were also
changed in APP/PS1xdb/db mice, we next asked
whether or not cytokine expression would also be modu-
lated in this T2D model. To test this, we again used
Luminex analysis to quantify expression of cytokines in
the cortex (Figs. 2 and Additional file 1: Figure S4).
PLSDA analysis identified that APP/PS1, db/db, and
combined APP/PS1xdb/db pathology were elevated on a
profile of cytokines compared to controls (Add-
itional file 1: Figure S4). Focusing our analysis to distin-
guish differences between the APP/PS1xdb/db combined
pathology and each individual pathology, we identified
two cytokine profiles, LV1 and LV2, that distinguished
between groups (Fig. 2b). LV2 distinguished APP/PS1
from db/db diabetic pathology (Fig. 2b, e, f). Scoring
samples on this profile revealed that animals with db/db
Fig. 1 APP/PS1 pathology and STZ cooperatively promote cytokine expression. a Luminex analysis of 22 cytokines (columns, z-scored) expressed
in the cortex of APP/PS1, STZ, and APP/PS1-STZ mice (each row is a cortex sample). b Partial least squares discriminant analysis (PLSDA) identified
two profiles of cytokines, LV1 and LV2, that distinguished groups. LV1 separated APP/PS1-STZ mice (positive) from both APP/PS1 and STZ mice
(negative). LV2 separated STZ mice (positive) from APP/PS1 mice (negative). c The weighted profile of cytokines representing LV1. Errors bars on
each cytokine were computed by PLSDA model regeneration using iterative subsampling of 80% of samples (mean ± SD). d Scoring the data for
each sample in a on LV1 revealed that combined APP/PS1-STZ pathology cooperatively increased the LV1 cytokine profile compared to either
APP/PS1 or STZ pathology alone (***p < 0.001, Welch’s ANOVA with Dunnett’s T3 test). e The weighted profile of cytokines representing LV2.
Errors bars on each cytokine were computed by PLSDA model regeneration using iterative subsampling of 80% of samples (mean ± SD). f Scoring
the data for each sample in b on LV2 revealed that STZ is significantly upregulated on the LV2 cytokine profile compared to APP/PS1 (*p < 0.05,
Welch’s ANOVA with Dunnett’s T3 test). Data were collected from 21 mice (16 M/12/F, STZ5M/2F, APP/PS1 3 M/4F, APP/PS1-STZ 4 M/3F)
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pathology are elevated on this profile, regardless of the
presence of APP/PS1 pathology (Fig. 2f). More interest-
ingly, however, LV1 distinguished APP/PS1xdb/db mice
from APP/PS1 pathology alone or db/db alone (Fig. 2b–
d). Analysis of each cytokine on an individual basis
showed a similar trend (Additional file 1: Figure S5).
Like in the STZ T1D model, the most upregulated cyto-
kines distinguishing APP/PS1xdb/db mice from either
APP/PS1 or db/db mice had strongly chemotactic or
pro-inflammatory properties (i.e., MIP-1α, MIP-1β).
High-fat diet cooperatively stimulates cytokine
production in APP/PS1 mice
Since Alzheimer’s (APP/PS1) and TD2 (db/db) pathologies
cooperated to increase expression of diverse cytokines be-
yond either pathology alone (Fig. 2), we next asked if
Fig. 2 APP/PS1 and db/db pathologies cooperatively promote cytokine expression. a Luminex analysis of 22 cytokines (columns, z-scored)
expressed in the cortex of APP/PS1, db/db, and APP/PS1xdb/db mice (each row is a cortex sample). b PLSDA identified two profiles of cytokines,
LV1 and LV2, that distinguished groups. LV1 separated APP/PS1xdb/db mice (positive) from both APP/PS1 and db/db mice (negative). LV2
separated STZ mice (positive) from APP/PS1 mice (negative). c The weighted profile of cytokines representing LV1. Errors bars on each cytokine
were computed by PLSDA model regeneration using iterative subsampling of 80% of samples (mean ± SD). d Scoring the data for each sample in
b on LV1 revealed that combined APP/PS1xdb/db pathology cooperatively increased the LV1 cytokine profile compared to either APP/PS1 or db/
db pathology alone (**p < 0.01, Welch’s ANOVA with Dunnett’s T3 test). e The weighted profile of cytokines representing LV2. Errors bars on each
cytokine were computed by PLSDA model regeneration using iterative subsampling of 80% of samples (mean ± SD). f Scoring the data for each
sample in b on LV2 revealed that APP/PS1xdb/db is significantly upregulated on the LV2 cytokine profile compared to db/db (*p < 0.05, Welch’s
ANOVA with Dunnett’s T3 test). Data were collected from 21 animals (14 M/14F, APP/PS1 2 M/51F, db/db 3 M/5F, APP/PS1xdb/db 6 M/1F)
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prediabetic conditions would have a similar effect. To test
this, we exposed APP/PS1 mice to high-fat diet (HFD, see
the “Materials and methods” section) for 5–6months. We
then quantified the same panel of 22 cytokines from mouse
cortical tissues (Fig. 3, Additional file 1: Figure S6). Using
PLSDA analysis to identify a profile of cytokines most up-
regulated in response to APP/PS1 and HFD pathology, we
observed that HFD combined with APP/PS1 pathology ele-
vated a profile of cytokines compared to wild-type controls
(Additional file 1: Figure S6B-C).
Again, we used PLSDA to evaluate the differences be-
tween combined APP/PS1-HFD pathology and either
APP/PS1 or HFD alone (Fig. 3b). Similar to our findings
with db/db mice, we identified an LV1 that separated APP/
Fig. 3 APP/PS1 pathology and high-fat diet cooperatively promote cytokine expression. a Luminex analysis of 22 cytokines (columns, z-scored)
expressed in the cortex of APP/PS1, HFD, and APP/PS1-HFD mice (each row is a cortex sample). b PLSDA identified two profiles of cytokines, LV1
and LV2, that distinguished groups. LV1 separates APP/PS1-HFD mice (positive) from both APP/PS1 and HFD mice (negative). LV2 separates HFD
mice (positive) from APP/PS1 and APP/PS1-HFD mice (negative). c The weighted profile of cytokines representing LV1. Errors bars on each
cytokine were computed by PLSDA model regeneration using iterative subsampling of 80% of samples (mean ± SD). d Scoring the data for each
sample in a on LV1 revealed that combined APP/PS1-HFD pathology cooperatively increased the LV1 cytokine profile compared to either APP/
PS1 or db/db pathology alone (**p < 0.01, Welch’s ANOVA with Dunnett’s T3 test). e The weighted profile of cytokines representing LV2. Errors
bars on each cytokine were computed by PLSDA model regeneration using iterative subsampling of 80% of samples (mean ± SD). f Scoring the
data for each sample in b on LV2 revealed that HFD is significantly upregulated on the LV2 cytokine profile compared to both APP/PS1 and APP/
PS1-HFD (**p < 0.01, Welch’s ANOVA with Dunnett’s T3 test). Data were collected from 21 animals (11 M/10F, HFD 4 M/3F, APP/PS1 3 M/4F,
APP/PS1-HFD 4 M/3F)
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PS1-HFD from both HFD and APP/PS1 groups (Fig. 3c, d)
and a second profile, LV2, that separated HFD only from
both other groups (Fig. 3e, f). LV1 consisted of a weighted
combination of cytokines that were particularly elevated in
response to combined APP/PS1-HFD. Importantly, the top
correlates with APP/PS1-HFD on LV1 included MIP-1α,
IL-1β, eotaxin, and IL-17, reflecting the chemotactic and
pro-inflammatory properties of cytokines found in the
combined models in Figs. 1 and 2. We also found that top
cytokines from LV1 followed a similar trend to the samples
scored on LV1 (Fig. 3d and Additional file 1: Figure S7).
Plasma Aβ correlates with brain cytokines in APP/PS1xdb/
db mice
Given that T2D diabetes, as modeled by db/db and HFD
mice, amplified brain Aβ levels (Additional file 1: Figure
S1B) and enhanced pro-inflammatory cytokine produc-
tion (Figs. 2 and 3), we next hypothesized that peripheral
plasma levels would correlate with brain cytokine ex-
pression in APP/PS1xdb/db mice. We found that plasma
Aβ levels quantified from blood collected at euthanasia
were lower in APP/PS1xdb/db mice (Aβ40 *p = 0.014 vs.
APP/PS1; Aβ40 p = 0.085) (Figs. 4a, d). To identify a re-
lationship between Aβ and cytokines, we used PLSR ana-
lysis to regress brain tissue cytokine measurements
against plasma measurements of Aβ1-40 or Aβ1-42 from
the same animals (Fig. 4). In APP/PS1 mice, we found
that elevated plasma Aβ1-42 was correlated with in-
creased expression of a number of anti-inflammatory cy-
tokines, including IL-10 and IL-4 (Figs. 4b, c). In
contrast, high plasma Aβ1-42 correlated with primarily
pro-inflammatory cytokines in APP/PS1xdb/db mice, in-
cluding IL-3, IL-17, and KC (CXCL1). In terms of Aβ1-
40, PLSR analysis revealed that increased plasma levels
were associated with increased IL-4 and broad suppres-
sion of pro-inflammatory cytokines whereas pro-
inflammatory cytokines were elevated in APP/PS1xdb/
db mice with low plasma levels (Figs. 4e, f). These data
suggest a complex relationship between neuroinflamma-
tion and pathology in line with previous observations in
APP/PS1xdb/db mice in which the overall inflammation
is exacerbated in SP-free areas [17].
Glucose and insulin correlate with brain cytokines in APP/
PS1xdb/db mice
T2D models stimulate Aβ pathology and cytokine ex-
pression (Figs. 2 and 3). Since T2D drives dysregulation
of glucose and insulin, we concluded this study by ask-
ing if these variables correlated with brain cytokine
levels. While we found that high glucose strongly corre-
lated with brain cytokines in db/db mice, we found that
high glucose most strongly correlated with elevated anti-
inflammatory IL-4 in APP/PS1xdb/db mice (Fig. 5a, b).
In contrast, low insulin strongly correlated with a
strongly pro-inflammatory signature, including MIP-1β,
KC (CXCL1), and IL-13 in both db/db and APP/
PS1xdb/db mice (Fig. 5c, d). These findings indicate that
neuroinflammation is tightly linked to glucose and insu-
lin levels, even in the db/db genetic mouse model.
Discussion
The close relationship between diabetes and AD has
been long explored, both in epidemiological studies [5,
6] and murine models [11, 17]. Although the underlying
mechanisms by which diabetes promotes AD pathogen-
esis have not been elucidated, previous research supports
multi-faceted dysfunction caused by diabetes, including
neuronal insulin signaling, mitochondrial dysfunction,
and inflammation [42, 43]. Inflammation is a relevant
feature of AD and diabetes and it plays critical roles in
the pathogenesis of both diseases [43]. To our know-
ledge, this is the first study to holistically analyze com-
plex cytokine profiles in mixed models harboring
prediabetes, T1D, or T2D together with amyloid path-
ology relevant to AD. Our analysis revealed that diabetic
or prediabetic pathologies cooperatively modulated ex-
pression of pro-inflammatory cytokines in the brains of
APP/PS1 mice and showed that profiles of expressed cy-
tokines strongly correlated with circulating glucose
levels.
Our study employed classical models of prediabetes
and T1D in APP/PS1 mice. As previously described,
HFD-induced prediabetes leads to severe hyperinsuline-
mia that modulates glucose levels, while STZ adminis-
tration results in a well-characterized model of T1D
with low insulin and high glucose levels. We also in-
cluded a newer mixed animal model of AD-T2D, by
crossing APP/PS1 with db/db mice [17, 31]. These mice
are severely overweight, and they present insulin resist-
ance. In this context, high insulin levels fail to control
hyperglycemia. Within the brain, APP/PS1xdb/db mice
showed increased tau phosphorylation that initially af-
fects the cortex and spreads to the hippocampus [17,
31]. We also previously observed that APP/PS1xdb/db
mice exhibit a shift in the kinetics of Aβ deposition, and
while more toxic soluble Aβ species are increased, insol-
uble Aβ and senile plaques are reduced [17, 31]. In APP/
PS1xdb/db mice, we also observed that plasma Aβ levels
were reduced when compared with APP/PS1 mice. Al-
though still controversial, our data are in line with the
“peripheral sink” hypothesis of Aβ [44–46]. In this con-
text, reduced plasma Aβ in APP/PS1xdb/db mice sup-
ports the observed increase in brain soluble Aβ levels.
Other studies using similar mouse models have also de-
tected changes in Aβ. In particular, Niedowicz et al. [47]
did not detect significant changes in cortical Aβ depos-
ition; however, the combination of AD and T2D in-
creased oligomeric Aβ in the brain. Also, while total Aβ
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levels are not altered in young APP23xob/ob mice, these
mice have been found to present an increase in amyloid
angiopathy [48]. Because of reported pathological differ-
ences between combined AD/diabetic models, our
present study includes models of three different meta-
bolic alterations relevant to diabetes, enabling us to
make robust conclusions about the chronic effects of
diabetes on cytokine expression in the AD brain.
While cytokines have traditionally been divided into
pro- and anti-inflammatory categories, they are often
pleiotropic, and cytokines with opposing functions are
often expressed together. Moreover, the complexity of
the neuroinflammatory response may be magnified when
multiple chronic inflammatory processes present to-
gether, as with APP/PS1xdb/db mice. These complex al-
terations necessitate simultaneous measurement and
analysis of a panel of cytokines to understand the effects
of diabetic pathology on neuroinflammation in APP/PS1
AD mice. As our group has previously shown, PLSR ana-
lysis provides a powerful tool to detect changes in
Fig. 4 Plasma amyloid levels correlated with distinct signatures of brain cytokine expression in APP/PS1 or APP/PS1xdb/db mice. a Plasma Aβ1-42
levels were significantly decreased in APP/PS1xdb/db compared to APP/PS1 mice (mean ± SEM; *p < 0.05, Student’s t test). b Distinct profiles of
cytokines correlated with Aβ1-42 levels in db/db or APP/PS1xdb/db mice (mean ± SD in an iterative subsampling of 80% of samples). c Plasma
Aβ1-42 levels were decreased in APP/PS1xdb/db compared to APP/PS1 mice and significantly correlated with brain composite cytokine score on
LV1. d Plasma Aβ1-40 levels trend towards a decrease in APP/PS1xdb/db compared to APP/PS1 mice (mean ± SEM; p = 0.085, Student’s t test) e
Distinct profiles of cytokines correlated with Aβ1-40 levels in db/db or APP/PS1xdb/db mice, ordered with respect to b (mean ± SD in an iterative
subsampling of 80% of samples). f Plasma Aβ1-40 concentration was decreased in APP/PS1xdb/db compared to controls significantly correlated
with brain composite cytokine score on LV1. Data were collected from ten animals (4 M/6F, APP/PS1 1 M/4F, APP/PS1xdb/db 3 M/2F)
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cytokine expression associated within a pathological
group or with measures of pathological severity. More-
over, the profiles of cytokines generated on each LV pro-
vide a ranking of the relative importance of each
cytokine in distinguishing among groups, enabling us to
identify the functions of top cytokines involved in each
separation. In the present study, we used this same
(PLSDA) approach to identify profiles of cytokines that
were most different between single AD or diabetic path-
ologies, and in combined APP/PS1xdiabetic or APP/
PS1xprediabetic mice. Regardless of the diabetic insult
(HFD, STZ, db/db), our data revealed that diabetic con-
ditions cooperated with APP/PS1 pathology to strongly
upregulate cytokine expression in the combined model.
We note that there were few differences between 6-
month-old wild-type and APP/PS1 mice, due to this
being an early pathological time point in this model [29],
while prediabetes or diabetes animal models produce
broad inflammation at earlier time points [49]. There-
fore, the severity of combined diabetic and APP/PS1
pathology precludes studying the effects of advanced age
using these models.
Since the goal of the present study was to determine
the effects of combined AD-diabetic pathology, we con-
ducted our analyses comparing each diabetic model to
APP/PS1 mice in the absence of diabetic pathology. The
LV1 cytokine profile for each of these models signifi-
cantly separated combined APP/PS1 and diabetic/predi-
abetic mice from either pathology alone. The top
cytokines associated with combined APP/PS1 and dia-
betic/prediabetic pathology in all three metabolic models
had pro-inflammatory and chemotactic properties (e.g.,
Fig. 5 Plasma glucose and insulin levels correlate with brain cytokine expression in db/db and mixed models. a Profiles of cytokines correlated
with glucose levels in db/db or APP/PS1xdb/db mice (mean ± SD in an iterative subsampling of 80% of samples). b Glucose levels significantly
correlate with brain composite cytokine score on LV1. c Profiles of cytokines correlated with insulin levels in db/db or APP/PS1xdb/db mice
ordered with respect to a (mean ± SD in an iterative subsampling of 80% of samples). d Plasma insulin concentration significantly correlated with
brain composite cytokine score on LV1. Data were collected from 14 animals (8 M/6F, db/db 2 M/5F, APP/PS1xdb/db 6 M/1F)
Sankar et al. Journal of Neuroinflammation           (2020) 17:38 Page 10 of 15
MIP-1β, MIP-1α, MCP-1, IFN-γ) [50–53]. Top corre-
lates in each LV1 identified chemokines (MCP-1 in
APP/PS1-STZ, MIP-1α and MIP-1β in APP/PS1xdb/db,
MIP-1α in APP/PS1-HFD) that were only significantly
upregulated in the presence of combined pathology
(Figs. 1, 2, and 3, Additional file 1: Figures S3, S5, S7),
emphasizing that the combined presence of amyloid and
metabolic pathologies cooperatively modulates the neu-
roinflammatory environment.
We also used PLSR analysis to identify profiles of
brain cytokines that were strongly correlated with in-
creased plasma glucose or insulin in our mixed APP/
PS1xdb/db (AD-T2D) model. Cytokines, as inflamma-
tory markers, have been previously analyzed in diabetic
patients [54, 55] and diabetes animal models [56, 57].
Our PLSR-based profiling analysis confirmed some pre-
vious observations on individual cytokines. First, the
strongest glucose-cytokine signals identified by the
model included granulocyte-macrophage colony-
stimulating factor (GM-CSF), IFN-γ, and IL-3, all of
which appeared within the top six correlates for LV1
based on the PLSDA analysis (Fig. 2). Of these, GM-CSF
promotes inflammation in various infectious and inflam-
matory diseases, and it is implicated in monocyte/
macrophage activation [58]. Previous studies of diabetes
patients have reported that circulating GM-CSF levels
are not affected [59]; however, it has also been shown
that GM-CSF levels are increased in diabetes [55, 60, 61]
as well as in prediabetic patients, correlating with glyco-
sylated hemoglobin [62]. Likewise, studies in T2D pa-
tients show that insulin and oral hypoglycemic agents
may reduce serum GM-CSF levels in T2D patients [61].
Additionally, intracerebral GM-CSF administration to
APP/PS1 mice directly increases blood-brain barrier
endothelial permeability, suggesting that high levels of
GM-CSF detected in the brain parenchyma and CSF of
AD patients may induce blood-brain barrier opening.
Moreover, GM-CSF blockade abolishes monocyte infil-
tration in the brain from APP/PS1 mice [58]. Also, GM-
CSF administration in a phase Ib/II clinical trial on renal
cell carcinoma has been associated with acute multifocal
cerebral venous thrombosis and subdural and subarach-
noid hemorrhage [63]. Since diabetes also affects vascu-
lar integrity and blood-brain barrier [64], it is feasible
that the increased spontaneous central bleeding ob-
served in APP/PS1xdb/db mice [17, 31] is related, at
least in part, to GM-CSF-glucose association.
PLSR analysis revealed that IFN-γ was also a top cor-
relate with high glucose levels in AD-T2D mice because
it has been previously identified as an inflammatory me-
diator in AD [65]. IFN-γ plasma levels correlated with
glycosylated hemoglobin, which is a biomarker of aver-
age glucose levels, in prediabetic patients [62]. Higher
levels of IFN-γ were also detected in T2D patients [66],
leading to beta-cell dysfunction. Moreover, IFN-γ may
play a role in the genesis of insulin resistance [67]. Also,
abnormally high levels of IFN-γ protein are detected in
brain and blood serum of diabetic mice, and blocking
IFN-γ has been shown to restore microglial chemotactic
response to vascular damage [68]. Intracerebral
hemorrhage is also associated with high levels of IFN-γ
[69, 70]. Blood-brain barrier alterations and chronic in-
flammation are classical pathological features of cerebral
small vessel disease, characterized by multiple strokes,
blood-brain barrier dysfunction, and chronic inflamma-
tion at the neurovascular unit [71]. In line with these ob-
servations, db/db [72] and APP/PS1xdb/db mice [17, 31]
show widespread spontaneous bleeding. In this context,
IFN-γ may lead to diffuse neuron and oligodendrocyte
damage [71].
IL-17 was also upregulated in all three diabetic models
and was highly correlated with peripheral Aβ1-42 and
with glucose levels in db/db mice. IL-17 is the most ef-
fective cytokine of T helper 17 cells and plays a pro-
inflammatory role in chronic inflammation [73] observed
in T2D [74]. Also, IL-17 production has been associated
with cerebral small vessel disease, similar to that
observed in db/db and APP/PS1xdb/db mice [75], and
IL-17 might contribute to atherosclerosis development.
Moreover, IL-17 has been implicated in the neuroin-
flammatory response in AD [76], and while some
controversial studies show a protective role for IL-17
against the risk for T2D [77], others support a crucial
role for IL-17 in inflammation, insulin resistance, and
T2D [66, 78]. In line with these studies, IL-17 levels are
also increased in the hippocampus from db/db mice
[73], and antibodies targeting Th17 cells have been stud-
ied in an effort, to protect individuals at risk for develop-
ing diabetes [79]. These data support that metabolic
alterations can broadly trigger and exacerbate brain neu-
roinflammation and production of cytokines known to
promote T2D and AD pathogenesis [36, 79].
PLSR analysis also revealed changes in cytokine
expression associated with high insulin levels and insulin
resistance in our mixed AD-T2D model, and both insu-
lin and insulin resistance are major contributors to
central complications in AD and T2D [4]. IL1-α, IL-5,
IL-12p70, tumor necrosis factor (TNF-α), and IL1-β are
highly correlated with insulin levels in APP/PS1xdb/db
mice. IL-1 family of cytokines plays a relevant role in the
response to inflammatory stress, in close association
with T2D. Previous studies have shown that insulin fa-
vors a pro-inflammatory state via insulin receptor, glu-
cose metabolism, production of reactive oxygen species,
and secretion of IL-1 [80]. Also, pancreatic β-cell IL-1
expression is increased in T2D patients [81]. In this
sense, IL1-α and β blockage show an improvement in in-
sulin secretion and glycaemia [82]. In line with these
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observations, IL-1β has been reported to lead to the re-
duction of insulin-induced glucose uptake and insulin
resistance [83]. In short-term studies with mice on high-
fat diet, serum IL-1α and IL-1β do not seem to be
affected [84]. However, longer exposure to HFD and in-
sulin resistance increases IL-1β mRNA in the hippocam-
pus [85]. IL-1β has also been proposed as a contributor
to the onset of AD [86]. Likewise, studies in non-obese
diabetic mice have reported that IL-1α is increased in
plasma and insulin therapy increases IL-1α release in
splenocytes [87]. Moreover, IL-1 usually synergizes with
TNF-α, since both cytokines are produced at sites of
local inflammation [81]. On the other hand, TNF-α has
been shown to cause cellular insulin resistance in hypo-
thalamic neurons [88]. Also, prediabetes with high insu-
lin levels appears to increase TNF-α in patients [62].
Similar outcomes have been observed in prediabetic
mice, in which long-term exposure to high-fat diet and
insulin resistance increases TNF-α protein in the hippo-
campus [85]. Moreover, increased levels of TNF-α are
detected in diabetic patients and may serve as a prognos-
tic tool for diabetic retinopathy [78]. Central administra-
tion of Aβ oligomers induces peripheral glucose
intolerance. However, this effect is avoided in TNF-α re-
ceptor 1 knockout mice, supporting a role for TNF-α in
the two-way crosstalk between AD and diabetes [89].
The second top correlate with insulin in APP/PS1xdb/
db mice was IL-5. Certain studies have found IL-5 to be
reduced in diabetes [78], while others have found IL-5
plasma levels to be correlated with glycosylated
hemoglobin in diabetic patients [62]. Similarly, increased
levels of IL-5 have been shown in HFD-fed mice [90].
We also found IL-12p70 and IL-13 to be closely related
to high insulin levels in APP/PS1xdb/db mice, both of
which have been shown to be elevated in prediabetic pa-
tients [62]. A similar trend has been observed for IL-
12p70 in HFD-fed mice [91]. Altogether, multivariate
analysis of cytokine expression in the cortex from our
mixed model indicates that there are marked pro-
inflammatory differences in cytokine profiles associated
with the co-presentation of T2D and AD pathologies.
Our findings in the current study motivate a number
of future avenues of research. First, although we have
found that diabetic pathology robustly increased cyto-
kine expression in cortical tissues, with or without amyl-
oid pathology, we have not identified the cell type
expressing each one. Given that metabolic dysregulation
particularly affects neurons, it is possible that neurons
contribute to cytokine expression, as we have recently
found in the context of brain injury [35]. Although we
note that neuroinflammatory response is also mediated
by astrocytes, prior studies in our lab [31] have revealed
limited differences in astrocyte burden in APP/PS1xdb/
db compared to APP/PS1 animals. Nevertheless, more
detailed future astroglial studies should be carried out in
different metabolic disease-AD models. Second, given
that cytokine expression is regulated by intracellular
phospho-signaling pathways, it is likely we will identify
dysregulation of central signaling pathways, such as
PI3K/Akt, NFκB, or MAPK, that may be targeted using
small molecules to modulate neuroinflammation. Finally,
it remains unknown if metabolism normalizing therap-
ies, such as insulin, have the potential to reduce the neu-
roinflammatory signatures identified here.
Conclusions
In total, our multiplexed analysis of cytokines shows that
Alzheimer’s and diabetic pathologies cooperate to en-
hance profiles of cytokines reported to be involved in
both diseases. Our analysis identified pro-inflammatory
cytokines that were upregulated in prediabetic, T2D dia-
betic, and T1D diabetic models. Therefore, these data
suggest that metabolic dysregulation drives neuroinflam-
mation, regardless of the underlying cause.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12974-020-1707-x.
Additional file 1: Figure S1. Metabolic assessment, amyloid pathology
and microglia burden are altered in mixed models of metabolic disease
and AD. Figure S2. APP/PS1-STZ pathology upregulates a profile of
cytokines compared to wild-type control. Figure S3. Individual cytokines
measured for APP/PS1, STZ, and APP/PS1-STZ groups. Figure S4. APP/
PS1xdbdb pathology upregulates a profile of cytokines compared to
wild-type controls. Figure S5. Individual cytokines measured for APP/PS1,
dbdb, and APP/PS1xdbdb groups. Figure S6. APP/PS1-HFD pathology
upregulates a profile of cytokines compared to wild-type controls. Figure
S7. Individual cytokines measured for APP/PS1, HFD, and APP/PS1-HFD
groups.
Acknowledgements
We thank the University of Cadiz Animal Facility, Ms. Consuelo Rivera, and
Mr. Miguel Angel Rodriguez for their help and technical support.
Authors’ contributions
SBS and CIG contributed to the data acquisition, analysis, interpretation, and
manuscript drafting. LDW, JJR, CHI, and CFP contributed to the data
acquisition and analysis. LBW and MGA contributed to the study concept
and design, analysis, drafting, and critical revision of manuscript for
intellectual content. All authors read and approved the final manuscript.
Funding
This work was funded in part by Programa Estatal de I+D+I orientada a los
Retos de la Sociedad (BFU 2016-75038-R), financed by the Agencia Estatal de
Investigación (AEI) and the Fondo Europeo de Desarrollo Regional (FEDER),
Ministerio de Ciencia, Innovación y Universidades, Explora Ciencia, Ministerio
de Ciencia, Innovación y Universidades (BFU2017-91910-EXP), Subvención
para la financiación de la investigación y la innovación biomédica y en cien-
cias de la salud en el marco de la Iniciativa Territorial Integrada 2014–2020
para la provincia de Cádiz, Consejeria de Salud, Junta de Andalucia, Union
Europea, financed by the Fondo de Desarrollo Regional (FEDER) (PI-0008-
2017) (M.G.A.). This work was also supported by startup funds from the
George W. Woodruff School of Mechanical Engineering at Georgia Tech
(L.B.W.) and by the National Institutes of Health under grant number R33
ES025661 04S1. LDW was supported in part by the National Institutes of
Sankar et al. Journal of Neuroinflammation           (2020) 17:38 Page 12 of 15
Health Cell and Tissue Engineering Biotechnology Training Grant (T32-
GM008433). Authors declare no conflict of interest.
Availability of data and materials
Data is available upon reasonable request.
Ethics approval and consent to participate
All experimental procedures were approved by the Animal Care and Use
Committee of the University of Cadiz, in accordance with the Guidelines for
Care and Use of experimental animals (European Commission Directive
2010/63/UE and Spanish Royal Decree 53/2013).
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Author details
1Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute
of Technology, Atlanta, GA 30332, USA. 2Division of Physiology, School of
Medicine, Universidad de Cadiz, Instituto de Investigacion Biomedica de
Cadiz (INIBICA), Cadiz, Spain. 3Instituto de Investigación e Innovación
Biomédica de Cádiz (INiBICA), Cádiz, Spain. 4Departamento de Fisiología,
Facultad de Ciencias de la Salud, Universidad de Granada, Granada, Spain.
5Área de Inmunología, Facultad de Medicina, Universidad de Cádiz, Cádiz,
Spain. 6George W. Woodruff School of Mechanical Engineering and Parker H.
Petit Institute for Bioengineering & Bioscience, Georgia Institute of
Technology, 315 Ferst Dr, Rm 3303, Atlanta, GA 30332, USA.
Received: 28 August 2019 Accepted: 8 January 2020
References
1. Gaugler J, James B, Johnson T, Marin A, Weuve J, As A. Alzheimer’s disease
facts and figures. Alzheimers Dement. 2019;2019(15):321–87.
2. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological
alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011;1:
a006189.
3. Spires-Jones TL, Hyman BT. The intersection of amyloid beta and tau at
synapses in Alzheimer’s disease. Neuron. 2014;82:756–71.
4. Arnold SE, Arvanitakis Z, Macauley-Rambach SL, Koenig AM, Wang HY,
Ahima RS, Craft S, Gandy S, Buettner C, Stoeckel LE, et al. Brain insulin
resistance in type 2 diabetes and Alzheimer disease: concepts and
conundrums. Nat Rev Neurol. 2018;14:168–81.
5. Biessels GJ, Despa F. Cognitive decline and dementia in diabetes mellitus:
mechanisms and clinical implications. Nat Rev Endocrinol. 2018;14(10):591–
604. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397437/.
6. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia
in diabetes mellitus: a systematic review. Lancet Neurol. 2006;5:64–74.
7. Wu L, Yu C, Jiang H, Tang J, Huang HL, Gao J, Zhang X. Diabetes mellitus
and the occurrence of colorectal cancer: an updated meta-analysis of
cohort studies. Diabetes Technol Ther. 2013;15:419–27.
8. Baker LD, Cross DJ, Minoshima S, Belongia D, Watson GS, Craft S. Insulin
resistance and Alzheimer-like reductions in regional cerebral glucose
metabolism for cognitively normal adults with prediabetes or early type 2
diabetes. Arch Neurol. 2011;68:51–7.
9. Ramos-Rodriguez JJ, Spires-Jones T, Pooler AM, Lechuga-Sancho AM,
Bacskai BJ, Garcia-Alloza M. Progressive neuronal pathology and synaptic
loss induced by prediabetes and type 2 diabetes in a mouse model of
Alzheimer’s disease. Mol Neurobiol. 2017;54:3428–38.
10. Rdzak GM, Abdelghany O. Does insulin therapy for type 1 diabetes mellitus
protect against Alzheimer’s disease? Pharmacotherapy. 2014;34:1317–23.
11. Ramos-Rodriguez JJ, Infante-Garcia C, Galindo-Gonzalez L, Garcia-Molina Y,
Lechuga-Sancho A, Garcia-Alloza M. Increased spontaneous central bleeding
and cognition impairment in APP/PS1 mice with poorly controlled diabetes
mellitus. Mol Neurobiol. 2016;53:2685–97.
12. Craft S. The role of metabolic disorders in Alzheimer disease and vascular
dementia: two roads converged. Arch Neurol. 2009;66:300–5.
13. Nistico R, Cavallucci V, Piccinin S, Macri S, Pignatelli M, Mehdawy B, Blandini
F, Laviola G, Lauro D, Mercuri NB, D'Amelio M. Insulin receptor beta-subunit
haploinsufficiency impairs hippocampal late-phase LTP and recognition
memory. NeuroMolecular Med. 2012;14:262–9.
14. Zhao WQ, Townsend M. Insulin resistance and amyloidogenesis as common
molecular foundation for type 2 diabetes and Alzheimer’s disease. Biochim
Biophys Acta. 2009;1792:482–96.
15. Garcia-Alloza M, Gregory J, Kuchibhotla KV, Fine S, Wei Y, Ayata C, Frosch
MP, Greenberg SM, Bacskai BJ. Cerebrovascular lesions induce transient
beta-amyloid deposition. Brain. 2011;134:3697–707.
16. Weller RO, Subash M, Preston SD, Mazanti I, Carare RO. Perivascular drainage
of amyloid-beta peptides from the brain and its failure in cerebral amyloid
angiopathy and Alzheimer’s disease. Brain Pathol. 2008;18:253–66.
17. Infante-Garcia C, Ramos-Rodriguez JJ, Galindo-Gonzalez L, Garcia-Alloza M.
Long-term central pathology and cognitive impairment are exacerbated in
a mixed model of Alzheimer’s disease and type 2 diabetes.
Psychoneuroendocrinology. 2016;65:15–25.
18. Infante-Garcia C, Ramos-Rodriguez JJ, Hierro-Bujalance C, Ortegon E, Pickett
E, Jackson R, Hernandez-Pacho F, Spires-Jones T, Garcia-Alloza M.
Antidiabetic polypill improves central pathology and cognitive impairment
in a mixed model of Alzheimer’s disease and type 2 diabetes. Mol
Neurobiol. 2018;55:6130–44.
19. Plastino M, Fava A, Pirritano D, Cotronei P, Sacco N, Sperli T, Spano A, Gallo
D, Mungari P, Consoli D, Bosco D. Effects of insulinic therapy on cognitive
impairment in patients with Alzheimer disease and diabetes mellitus type-2.
J Neurol Sci. 2010;288:112–6.
20. Correia SC, Santos RX, Perry G, Zhu X, Moreira PI, Smith MA. Insulin-resistant
brain state: the culprit in sporadic Alzheimer’s disease? Ageing Res Rev.
2011;10:264–73.
21. Perez-Nievas BG, Stein TD, Tai HC, Dols-Icardo O, Scotton TC, Barroeta-Espar
I, Fernandez-Carballo L, de Munain EL, Perez J, Marquie M, et al. Dissecting
phenotypic traits linked to human resilience to Alzheimer’s pathology. Brain.
2013;136:2510–26.
22. Mehlhorn G, Hollborn M, Schliebs R. Induction of cytokines in glial cells
surrounding cortical beta-amyloid plaques in transgenic Tg2576 mice with
Alzheimer pathology. Int J Dev Neurosci. 2000;18:423–31.
23. Ruan L, Kang Z, Pei G, Le Y. Amyloid deposition and inflammation in APPswe/
PS1dE9 mouse model of Alzheimer’s disease. Curr Alzheimer Res. 2009;6:531–40.
24. Bate C, Kempster S, Last V, Williams A. Interferon-gamma increases neuronal
death in response to amyloid-beta1-42. J Neuroinflammation. 2006;3:7.
25. Wood LB, Winslow AR, Proctor EA, McGuone D, Mordes DA, Frosch MP,
Hyman BT, Lauffenburger DA, Haigis KM. Identification of neurotoxic
cytokines by profiling Alzheimer’s disease tissues and neuron culture
viability screening. Sci Rep. 2015;5:16622.
26. Ringheim GE, Szczepanik AM, Petko W, Burgher KL, Zhu SZ, Chao CC.
Enhancement of beta-amyloid precursor protein transcription and
expression by the soluble interleukin-6 receptor/interleukin-6 complex. Brain
Res Mol Brain Res. 1998;55:35–44.
27. Barroeta-Espar I, Weinstock LD, Perez-Nievas BG, Meltzer AC, Siao Tick
Chong M, Amaral AC, Murray ME, Moulder KL, Morris JC, Cairns NJ, et al.
Distinct cytokine profiles in human brains resilient to Alzheimer’s pathology.
Neurobiol Dis. 2019;121:327–37.
28. Jankowsky JL, Slunt HH, Gonzales V, Jenkins NA, Copeland NG, Borchelt DR.
APP processing and amyloid deposition in mice haplo-insufficient for
presenilin 1. Neurobiol Aging. 2004;25:885–92.
29. Garcia-Alloza M, Robbins EM, Zhang-Nunes SX, Purcell SM, Betensky RA, Raju
S, Prada C, Greenberg SM, Bacskai BJ, Frosch MP. Characterization of
amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer
disease. Neurobiol Dis. 2006;24:516–24.
30. Ramos-Rodriguez JJ, Ortiz-Barajas O, Gamero-Carrasco C, de la Rosa PR,
Infante-Garcia C, Zopeque-Garcia N, Lechuga-Sancho AM, Garcia-Alloza M.
Prediabetes-induced vascular alterations exacerbate central pathology in
APPswe/PS1dE9 mice. Psychoneuroendocrinology. 2014;48:123–35.
31. Ramos-Rodriguez JJ, Jimenez-Palomares M, Murillo-Carretero MI, Infante-
Garcia C, Berrocoso E, Hernandez-Pacho F, Lechuga-Sancho AM, Cozar-
Castellano I, Garcia-Alloza M. Central vascular disease and exacerbated
pathology in a mixed model of type 2 diabetes and Alzheimer’s disease.
Psychoneuroendocrinology. 2015;62:69–79.
32. Franklin KBJ, Paxinos G. The mouse brain in stereotaxic coordinates. San
Diego: Academic Press United States; 1997.
33. Kruger NJ. The Bradford Method for Protein Quantitation. In: Basic protein
and peptide protocols methods in molecular biology, vol. 32. Totowa:
Humana Press; 1994.
Sankar et al. Journal of Neuroinflammation           (2020) 17:38 Page 13 of 15
34. Jiménez-Palomares M, Ramos-Rodríguez JJ, López-Acosta JF, Pacheco-Herrero
M, Lechuga-Sancho AM, Perdomo G, García-Alloza M, Cózar-Castellano I.
Increased Aβ production prompts the onset of glucose intolerance and insulin
resistance. Am J Physiol Endocrinol Metab. 2012;302:E1373–80.
35. Sankar SB, Pybus AF, Liew A, Sanders B, Shah KJ, Wood LB, Buckley EM. Low
cerebral blood flow is a non-invasive biomarker of neuroinflammation after
repetitive mild traumatic brain injury. Neurobiol Dis. 2019;124:544–54.
36. Waisman A, Hauptmann J, Regen T. The role of IL-17 in CNS diseases. Acta
Neuropathol. 2015;129:625–37.
37. Rothwell NJ, Luheshi GN. Interleukin 1 in the brain: biology, pathology and
therapeutic target. Trends Neurosci. 2000;23:618–25.
38. Weber GF, Chousterman BG, He S, Fenn AM, Nairz M, Anzai A, Brenner T, Uhle
F, Iwamoto Y, Robbins CS, et al. Interleukin-3 amplifies acute inflammation and
is a potential therapeutic target in sepsis. Science. 2015;347:1260–5.
39. Brugger W, Bross K, Frisch J, Dern P, Weber B, Mertelsmann R, Kanz L.
Mobilization of peripheral blood progenitor cells by sequential
administration of interleukin-3 and granulocyte-macrophage colony-
stimulating factor following polychemotherapy with etoposide, ifosfamide,
and cisplatin. Blood. 1992;79:1193–200.
40. Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant
protein-1 (MCP-1): an overview. J Interf Cytokine Res. 2009;29:313–26.
41. Keating AK, Freehauf C, Jiang H, Brodsky GL, Stabler SP, Allen RH, Graham
DK, Thomas JA, Van Hove JL, Maclean KN. Constitutive induction of pro-
inflammatory and chemotactic cytokines in cystathionine beta-synthase
deficient homocystinuria. Mol Genet Metab. 2011;103:330–7.
42. Vieira MNN, Lima-Filho RAS, De Felice FG. Connecting Alzheimer’s disease
to diabetes: underlying mechanisms and potential therapeutic targets.
Neuropharmacology. 2018;136:160–71.
43. De Felice FG, Ferreira ST. Inflammation, defective insulin signaling, and
mitochondrial dysfunction as common molecular denominators connecting
type 2 diabetes to Alzheimer disease. Diabetes. 2014;63:2262–72.
44. Matsuoka Y, Saito M, LaFrancois J, Gaynor K, Olm V, Wang L, Casey E, Lu Y,
Shiratori C, Lemere C, Duff K. Novel therapeutic approach for the treatment
of Alzheimer’s disease by peripheral administration of agents with an
affinity to beta-amyloid. J Neurosci. 2003;23:29–33.
45. Henderson SJ, Andersson C, Narwal R, Janson J, Goldschmidt TJ, Appelkvist
P, Bogstedt A, Steffen AC, Haupts U, Tebbe J, et al. Sustained peripheral
depletion of amyloid-β with a novel form of neprilysin does not affect
central levels of amyloid-β. Brain. 2014;137:553–64.
46. Fan LY, Tzen KY, Chen YF, Chen TF, Lai YM, Yen RF, Huang YY, Shiue CY,
Yang SY, Chiu MJ. The relation between brain amyloid deposition, cortical
atrophy, and plasma biomarkers in amnesic mild cognitive impairment and
Alzheimer’s disease. Front Aging Neurosci. 2018;10:175.
47. Niedowicz DM, Reeves VL, Platt TL, Kohler K, Beckett TL, Powell DK, Lee TL, Sexton
TR, Song ES, Brewer LD, et al. Obesity and diabetes cause cognitive dysfunction in
the absence of accelerated β-amyloid deposition in a novel murine model of
mixed or vascular dementia. Acta Neuropathol Commun. 2014;2:64.
48. Takeda S, Sato N, Uchio-Yamada K, Sawada K, Kunieda T, Takeuchi D, Kurinami H,
Shinohara M, Rakugi H, Morishita R. Diabetes-accelerated memory dysfunction via
cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse
model with diabetes. Proc Natl Acad Sci U S A. 2010;107:7036–41.
49. Lontchi-Yimagou E, Sobngwi E, Matsha TE, Kengne AP. Diabetes mellitus
and inflammation. Curr Diab Rep. 2013;13:435–44.
50. Johnstone M, Gearing AJ, Miller KM. A central role for astrocytes in the
inflammatory response to beta-amyloid; chemokines, cytokines and reactive
oxygen species are produced. J Neuroimmunol. 1999;93:182–93.
51. Cho H, Hashimoto T, Wong E, Hori Y, Wood LB, Zhao L, Haigis KM, Hyman BT,
Irimia D. Microfluidic chemotaxis platform for differentiating the roles of soluble
and bound amyloid-β on microglial accumulation. Sci Rep. 2013;3:1823.
52. Peterson PK, Hu S, Salak-Johnson J, Molitor TW, Chao CC. Differential
production of and migratory response to beta chemokines by human
microglia and astrocytes. J Infect Dis. 1997;175:478–81.
53. Chung IY, Benveniste EN. Tumor necrosis factor-alpha production by
astrocytes. Induction by lipopolysaccharide, IFN-gamma, and IL-1 beta. J
Immunol. 1990;144:2999–3007.
54. Wang Z, Shen XH, Feng WM, Ye GF, Qiu W, Li B. Analysis of inflammatory
mediators in prediabetes and newly diagnosed type 2 diabetes patients. J
Diabetes Res. 2016;2016:7965317.
55. Chatzigeorgiou A, Harokopos V, Mylona-Karagianni C, Tsouvalas E, Aidinis V,
Kamper EF. The pattern of inflammatory/anti-inflammatory cytokines and
chemokines in type 1 diabetic patients over time. Ann Med. 2010;42:426–38.
56. Wen Y, Gu J, Li SL, Reddy MA, Natarajan R, Nadler JL. Elevated glucose and
diabetes promote interleukin-12 cytokine gene expression in mouse
macrophages. Endocrinology. 2006;147:2518–25.
57. Wang Y, Xu J, Liu Y, Li Z, Li X. TLR4-NF-kappaB signal involved in depressive-
like behaviors and cytokine expression of frontal cortex and hippocampus
in stressed C57BL/6 and ob/ob mice. Neural Plast. 2018;2018:7254016.
58. Shang S, Yang YM, Zhang H, Tian L, Jiang JS, Dong YB, Zhang K, Li B, Zhao
WD, Fang WG, Chen YH. Intracerebral GM-CSF contributes to
transendothelial monocyte migration in APP/PS1 Alzheimer’s disease mice. J
Cereb Blood Flow Metab. 2016;36:1978–91.
59. Cimini FA, D'Eliseo D, Barchetta I, Bertoccini L, Velotti F, Cavallo MG.
Increased circulating granzyme B in type 2 diabetes patients with low-grade
systemic inflammation. Cytokine. 2019;115:104–8.
60. Perlman AS, Chevalier JM, Wilkinson P, Liu H, Parker T, Levine DM, Sloan BJ, Gong
A, Sherman R, Farrell FX. Serum inflammatory and immune mediators are
elevated in early stage diabetic nephropathy. Ann Clin Lab Sci. 2015;45:256–63.
61. Surendar J, Mohan V, Pavankumar N, Babu S, Aravindhan V. Increased levels
of serum granulocyte-macrophage colony-stimulating factor is associated
with activated peripheral dendritic cells in type 2 diabetes subjects (CURES-
99). Diabetes Technol Ther. 2012;14:344–9.
62. Lucas R, Parikh SJ, Sridhar S, Guo DH, Bhagatwala J, Dong Y, Caldwell R, Mellor
A, Caldwell W, Zhu H. Cytokine profiling of young overweight and obese
female African American adults with prediabetes. Cytokine. 2013;64:310–5.
63. Hotton KM, Khorsand M, Hank JA, Albertini M, Kim KM, Wilding G, Salamat
MS, Larson M, Sondel P, Schiller JH. A phase Ib/II trial of granulocyte-
macrophage-colony stimulating factor and interleukin-2 for renal cell
carcinoma patients with pulmonary metastases: a case of fatal central
nervous system thrombosis. Cancer. 2000;88:1892–901.
64. Brook E, Mamo J, Wong R, Al-Salami H, Falasca M, Lam V, Takechi R. Blood-
brain barrier disturbances in diabetes-associated dementia: therapeutic
potential for cannabinoids. Pharmacol Res. 2019;141:291–7.
65. Niranjan R. Molecular basis of etiological implications in Alzheimer’s disease:
focus on neuroinflammation. Mol Neurobiol. 2013;48:412–28.
66. Arababadi MK, Nosratabadi R, Hassanshahi G, Yaghini N, Pooladvand V,
Shamsizadeh A, Hakimi H, Derakhshan R. Nephropathic complication of
type-2 diabetes is following pattern of autoimmune diseases? Diabetes Res
Clin Pract. 2010;87:33–7.
67. Reinehr T, Roth CL. Inflammation markers in type 2 diabetes and the
metabolic syndrome in the pediatric population. Curr Diab Rep. 2018;18:131.
68. Taylor S, Mehina E, White E, Reeson P, Yongblah K, Doyle KP, Brown CE.
Suppressing interferon-gamma stimulates microglial responses and repair of
microbleeds in the diabetic brain. J Neurosci. 2018;38:8707–22.
69. Huang P, Freeman WD, Edenfield BH, Brott TG, Meschia JF, Zubair AC. Safety
and efficacy of Intraventricular delivery of bone marrow-derived
mesenchymal stem cells in hemorrhagic stroke model. Sci Rep. 2019;9:5674.
70. Gao L, Lu Q, Huang LJ, Ruan LH, Yang JJ, Huang WL, ZhuGe WS, Zhang YL,
Fu B, Jin KL, ZhuGe QC. Transplanted neural stem cells modulate regulatory
T, γδ T cells and corresponding cytokines after intracerebral hemorrhage in
rats. Int J Mol Sci. 2014;15:4431–41.
71. Fu Y, Yan Y. Emerging role of immunity in cerebral small vessel disease.
Front Immunol. 2018;9:67.
72. Ramos-Rodriguez JJ, Ortiz O, Jimenez-Palomares M, Kay KR, Berrocoso E,
Murillo-Carretero MI, Perdomo G, Spires-Jones T, Cozar-Castellano I,
Lechuga-Sancho AM, Garcia-Alloza M. Differential central pathology and
cognitive impairment in pre-diabetic and diabetic mice.
Psychoneuroendocrinology. 2013;38:2462–75.
73. Ma S, Zhong D, Ma P, Li G, Hua W, Sun Y, Liu N, Zhang L, Zhang W. Exogenous
hydrogen sulfide ameliorates diabetes-associated cognitive decline by
regulating the mitochondria-mediated apoptotic pathway and IL-23/IL-17
expression in db/db mice. Cell Physiol Biochem. 2017;41:1838–50.
74. Coope A, Torsoni AS, Velloso LA. Mechanisms in endocrinology: metabolic
and inflammatory pathways on the pathogenesis of type 2 diabetes. Eur J
Endocrinol. 2016;174:R175–87.
75. Noz MP, Ter Telgte A, Wiegertjes K, Joosten LAB, Netea MG, de Leeuw FE,
Riksen NP. Trained immunity characteristics are associated with progressive
cerebral small vessel disease. Stroke. 2018;49:2910–7.
76. Zhang J, Ke KF, Liu Z, Qiu YH, Peng YP. Th17 cell-mediated
neuroinflammation is involved in neurodegeneration of abeta1-42-induced
Alzheimer’s disease model rats. PLoS One. 2013;8:e75786.
77. Brahimaj A, Ligthart S, Ghanbari M, Ikram MA, Hofman A, Franco OH,
Kavousi M, Dehghan A. Novel inflammatory markers for incident pre-
Sankar et al. Journal of Neuroinflammation           (2020) 17:38 Page 14 of 15
diabetes and type 2 diabetes: the Rotterdam Study. Eur J Epidemiol.
2017;32:217–26.
78. Hang H, Yuan S, Yang Q, Yuan D, Liu Q. Multiplex bead array assay of
plasma cytokines in type 2 diabetes mellitus with diabetic retinopathy. Mol
Vis. 2014;20:1137–45.
79. Abdel-Moneim A, Bakery HH, Allam G. The potential pathogenic role of IL-
17/Th17 cells in both type 1 and type 2 diabetes mellitus. Biomed
Pharmacother. 2018;101:287–92.
80. Dror E, Dalmas E, Meier DT, Wueest S, Thevenet J, Thienel C, Timper K,
Nordmann TM, Traub S, Schulze F, et al. Postprandial macrophage-derived
IL-1beta stimulates insulin, and both synergistically promote glucose
disposal and inflammation. Nat Immunol. 2017;18:283–92.
81. Banerjee M, Saxena M. Interleukin-1 (IL-1) family of cytokines: role in type 2
diabetes. Clin Chim Acta. 2012;413:1163–70.
82. Timper K, Seelig E, Tsakiris DA, Donath MY. Safety, pharmacokinetics, and
preliminary efficacy of a specific anti-IL-1alpha therapeutic antibody
(MABp1) in patients with type 2 diabetes mellitus. J Diabetes Complicat.
2015;29:955–60.
83. Lagathu C, Yvan-Charvet L, Bastard JP, Maachi M, Quignard-Boulange A, Capeau J,
Caron M. Long-term treatment with interleukin-1beta induces insulin resistance in
murine and human adipocytes. Diabetologia. 2006;49:2162–73.
84. Kaczmarczyk MM, Machaj AS, Chiu GS, Lawson MA, Gainey SJ, York JM,
Meling DD, Martin SA, Kwakwa KA, Newman AF, et al. Methylphenidate
prevents high-fat diet (HFD)-induced learning/memory impairment in
juvenile mice. Psychoneuroendocrinology. 2013;38:1553–64.
85. Dutheil S, Ota KT, Wohleb ES, Rasmussen K, Duman RS. High-fat diet
induced anxiety and anhedonia: impact on brain homeostasis and
inflammation. Neuropsychopharmacology. 2016;41:1874–87.
86. Griffin WS, Mrak RE. Interleukin-1 in the genesis and progression of and risk
for development of neuronal degeneration in Alzheimer’s disease. J Leukoc
Biol. 2002;72:233–8.
87. Strandell E, Kaas A, Hartoft-Nielsen ML, Bock T, Buschard K, Bendtzen K.
Cytokine production in NOD mice on prophylactic insulin therapy. APMIS.
1999;107:413–9.
88. Clemenzi MN, Wellhauser L, Aljghami ME, Belsham DD. Tumour necrosis
factor alpha induces neuroinflammation and insulin resistance in
immortalised hypothalamic neurones through independent pathways. J
Neuroendocrinol. 2019;31:e12678.
89. Clarke JR, Lyra ESNM, Figueiredo CP, Frozza RL, Ledo JH, Beckman D,
Katashima CK, Razolli D, Carvalho BM, Frazao R, et al. Alzheimer-associated
Abeta oligomers impact the central nervous system to induce peripheral
metabolic deregulation. EMBO Mol Med. 2015;7:190–210.
90. Denver P, Gault VA, McClean PL. Sustained high-fat diet modulates
inflammation, insulin signalling and cognition in mice and a modified xenin
peptide ameliorates neuropathology in a chronic high-fat model. Diabetes
Obes Metab. 2018;20:1166–75.
91. Johnson LA, Zuloaga KL, Kugelman TL, Mader KS, Morre JT, Zuloaga DG, Weber S,
Marzulla T, Mulford A, Button D, et al. Amelioration of metabolic syndrome-
associated cognitive impairments in mice via a reduction in dietary fat content or
infusion of non-diabetic plasma. EBioMedicine. 2016;3:26–42.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Sankar et al. Journal of Neuroinflammation           (2020) 17:38 Page 15 of 15
